Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

MASLD/MASH Learning Center

Latest News & Blogs

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants

September 2025

ALG-055009 is an oral thyroid hormone receptor beta (THR-β) agonist being evaluated for treating metabolic dysfunction-associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG-055009 and bioavailability/food effect. Part 1 was a single-ascending dose study in healthy participants randomized to ALG-055009 (0.1 to 4.0 mg) or placebo. Part 2 was a multiple-ascending dose study in participants with mild hyperlipidemia randomized...

Read More arrow

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH), formally known as nonalcoholic steatohepatitis (NASH), a progressive subtype of nonalcoholic fatty liver disease (NAFLD), remains a major global contributor to liver-related morbidity and mortality. In early 2024, a new therapeutic option, Resmetirom, a liver-directed thyroid hormone receptor beta (THR-β) agonist, became available in the United States for individuals with MASH having moderate to advanced liver fibrosis (F2-F3), offering a...

Read More arrow

Adjustable Intragastric Balloon for Metabolic Dysfunction-associated Steatotic Liver Disease-Enhanced Weight Loss and Histological Improvement

September 2025

CONCLUSION: aIGB effectively induces significant weight loss and improves metabolic and histological parameters in MASLD/MASH patients, with upward volume adjustments enhancing outcomes. The procedure demonstrated an excellent safety profile.

Read More arrow

Association of Kidney Stone Disease With Metabolic Dysfunction Associated Liver Disease and Metabolic Dysfunction Associated Steatohepatitis: A National Inpatient Sample Study

September 2025

CONCLUSION: Patients with SLD were found to have a higher prevalence of KSD. The more pronounced association in MASLD and the lower-than-expected contribution of other conditions involving dysregulation of metabolic homeostasis such as gout or diabetes highlights the central role of SLD in KSD pathogenesis.

Read More arrow

Glycogen Synthase Kinase 3 beta Hepatocyte Deletion Attenuates Ferroptosis and Metabolic Dysfunction-Associated Steatohepatitis in Mice

September 2025

CONCLUSION: Gsk3β^(△Hep) reduced liver injury, mitochondrial DNA release, inflammation, and fibrosis in mice with MASH, secondary to improved mitochondrial bioenergetics and reduced ferroptosis. Therefore, GSK3β may be a potential therapeutic target for human MASH.

Read More arrow

Gut microbiota: A key player for soluble dietary fiber in regulating inflammatory disease

September 2025

Soluble dietary fiber (SDF) plays a significant role in modulating immune responses, particularly in the context of inflammatory diseases. SDF enhances intestinal barrier integrity and regulates immune function by modulating the composition of the gut microbiota and increasing the production of beneficial microbial metabolites, such as short-chain fatty acids (SCFAs), 3-hydroxyoctadecaenoic acid, pentadecanoic acid, and bile acids. Current evidence suggests that SDF holds therapeutic potential...

Read More arrow

Mertk(+) Liver Sinusoidal Endothelial Cells Negatively Regulate PINK1 Related Mitophagy and Accelerate MASH

September 2025

CONCLUSION: Mertk negatively regulates PINK1-mediated mitophagy in LSECs through the p-ERK signaling pathway, thereby accelerating MASH progression. Therefore, LSECs deficient of Mertk should be a novel therapy for reversing PINK1-related mitophagy and MASH.

Read More arrow

Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care

September 2025

Cardiovascular disease remains the leading cause of mortality worldwide, with obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) serving as major upstream drivers. Current therapies largely address downstream risk factors, leaving a need for agents that modify the metabolic contributors to cardiovascular disease. Survodutide, a dual glucagon and glucagon-like peptide-1 receptor agonist, represents an emerging therapy with broad metabolic effects, including...

Read More arrow

Quantification of (18)F-FDG Delivery Rate for Liver Inflammation Using Shortened Dynamic PET Imaging Protocols

September 2025

Liver inflammation is a diagnostic hallmark of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of chronic metabolic dysfunction-associated steatotic liver disease. ^(18)F-FDG delivery rate (K (1)) in the liver, measured by dynamic PET with tracer kinetic modeling, has the potential to assess liver inflammation and diagnose MASH noninvasively. However, a 1-h scan protocol is typically used to generate the liver [Formula: see text], which is less practical for clinical use....

Read More arrow

Cannabis Improves Metabolic Dysfunction and Macrophage Signatures in Obese Mice

September 2025

Obesity rates continue to rise, highlighting the need for new treatments that are effective, safe, and widely accessible. Aligned with the easing of restrictions on cannabis use, interest in its therapeutic potential is evolving. As such, we examined the effects of the cannabis plant with high cannabidiol (CBD) content or high Δ⁹-tetrahydrocannabinol (THC) content on metabolic and immune dysregulation in obese mice. Briefly, female C57BL/6 mice were randomized into four groups (n=15/group): 1)...

Read More arrow

Shift work and metabolic dysfunction-associated steatotic liver disease: a systematic review of observational studies

September 2025

CONCLUSION: The systematic review supports an association between shift work and increased MASLD risk. Further prospective studies with rigorous designs and diverse populations, as well as stronger mechanistic evidence, are needed to establish a causal link between shift work and MASLD.

Read More arrow

Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is growing in prevalence around the world, with a current global prevalence rate of 38%. Although MASLD serves as an umberlla term, its subtype of metabolic dysfunction associated steatohepatitis (MASH) with a prevalence of 5-7%, can lead to adverse liver outcomes including cirrhosis and liver mortality. However, prevalence rates for MASLD/MASH vary by country and region of the world. With the increasing rates of type 2 diabetes...

Read More arrow

MASH: the nexus of metabolism, inflammation, and fibrosis

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of liver disease characterized by hepatocyte injury, inflammation, and fibrosis. The transition from metabolic dysfunction-associated steatotic liver disease (MASLD) to MASH is driven by the accumulation of toxic lipid and metabolic intermediates resulting from increased hepatic uptake of fatty acids, elevated de novo lipogenesis, and impaired mitochondrial oxidation. These changes promote hepatocyte stress and cell...

Read More arrow

In patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis, does semaglutide (2.4mg subcutaneously every week) improve liver histology compared to placebo, and is it safe?

September 2025

No abstract

Read More arrow

KYLO-0603, a novel liver-targeting, thyroid hormone receptor-beta agonist for the inhibition of MASH progression

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. Kylo-0603 is a novel agonist for the thyroid hormone receptor β (THR-β) that has been developed by merging the structures of three acetylgalactosamine (GalNAc)-modified ASPGR ligands with a triiodothyronine (T3) analog. This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse...

Read More arrow

Association Between Liver Fibrosis and Cause-Specific Mortality in Japanese Patients With Biopsy-Confirmed Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD

September 2025

CONCLUSION: HCC and extrahepatic malignancies were the leading causes of death in Japanese patients with MASLD. Liver fibrosis was a significant predictor of both all-cause and liver-related mortalities, but not nonliver-related mortality, highlighting its importance in follow-up strategies for MASLD. MASH may contribute to increased nonliver-related deaths. Further long-term studies are warranted.

Read More arrow

Association between invasive and noninvasive liver disease assessments and long-term clinical outcomes in MASLD

September 2025

CONCLUSIONS: These data confirm the importance of liver fibrosis as the main predictor of long-term MALO. FIB-4 may aid in risk assessment and in predicting outcomes in MASLD.

Read More arrow

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review

September 2025

Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a slowly progressive liver disease characterized by hepatic steatosis, inflammation, and fibrosis. Despite multiple therapeutic approaches under investigation, no globally approved standard pharmacotherapy currently exists. This systematic review aims to inform and enhance critical care and hepatology practice by synthesizing the most recent evidence on the pathogenesis and...

Read More arrow

Relationship of GDF15 with hepatic mitochondrial respiration is depending on the presence of fibrosis in obese individuals

September 2025

CONCLUSIONS: In humans with obesity, serum GDF15 correlates positively with hepatic mitochondrial respiration in persons without, but negatively in persons with hepatic fibrosis. Future studies are needed to investigate whether and how GDF15 affects hepatic mitochondrial respiration in a fibrosis-dependent manner and/or, conversely, how fibrosis might modulate hepatic GDF15 secretion through altered mitochondrial function.

Read More arrow

MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression

September 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most prevalent cause of chronic liver disease worldwide. Its pathogenesis is complex and not yet fully elucidated but is commonly explained by the "multiple hit" hypothesis, which suggests that pathological behaviours interact with an unfavourable genetic background and the presence of cardiovascular comorbidities. Recent evidence has highlighted a potential role of the gut microbiota in the onset and progression...

Read More arrow